Sugi Predict

Sugi Predict / Compounds / SCHEMBL598649

SCHEMBL598649

SCHEMBL598649

Cc1cc2c(Br)cccc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.50
▸ CYP1A2 P05177 3/20 0.50
▸ RXFP1 Q9HBX9 2/20 0.50
▸ HPGD P15428 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ AHR P35869 1/20 0.45
▸ HRH4 Q9H3N8 1/20 0.44
▸ NOS1 P29475 1/20 0.42
▸ AXL P30530 1/20 0.42
▸ NQO2 P16083 1/20 0.42
▸ FLT3 P36888 1/20 0.42
▸ ITK Q08881 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ ABCB11 O95342 1/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ ADRA2A P08913 1/20 0.38
▸ PTGS1 P23219 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31098173 1.00 GAA (0.50) GAACYP1A2RXFP1HPGDLMNA
SCHEMBL28290633 0.81 CA2 (0.44) GAACYP1A2RXFP1HPGDLMNA
SCHEMBL12755269 0.79 AHR (0.46) GAACYP1A2RXFP1AHRHRH4
SCHEMBL8230643 0.78 DAO (0.56) GAACYP1A2RXFP1HPGDLMNA
SCHEMBL29713806 0.78 DAO (0.56) GAACYP1A2RXFP1HPGDLMNA
SCHEMBL26551030 0.77 BRD4 (0.53) GAACYP1A2HPGDLMNAAHR
SCHEMBL29471220 0.77 BRD4 (0.53) GAACYP1A2HPGDLMNAAHR
SCHEMBL20259660 0.75 HPGD (0.50) GAACYP1A2RXFP1HPGDLMNA
SCHEMBL1353956 0.75 PARP1 (0.59) GAACYP1A2RXFP1HPGDHRH4
SCHEMBL470317 0.75 AHR (0.45) GAARXFP1AHRHRH4NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688149-A1 IRAK4 PROTACS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
US-20250263760-A1 MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2025-08-21 — — US disclosed
US-12319946-B2 Methods for producing modified bacteria for production of nitroaromatics UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2025-06-03 — — US disclosed
US-20240374588-A1 IRAK4 PROTACS ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
WO-2024209044-A1 IRAK4 PROTACS ASTRAZENECA AB (SE) 2024-10-10 — — WO disclosed
EP-3928836-B1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-09-18 — — EP disclosed
US-20240229090-A1 MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-07-11 — — US disclosed
US-20240229090-A1 MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-07-11 — — US disclosed
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-18 — — US disclosed
US-20240067667-A1 ORGANIC COMPOUND, MIXTURE, COMPOSITION, AND ORGANIC ELECTRONIC DEVICE SHENZHEN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) 2024-02-29 — — US disclosed
US-20110178063-A1 BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES GLAXO GROUP LIMITED (GB) 2011-07-21 — — US disclosed
EP-2206698-A1 Ethynylindole compounds ONO Pharmaceutical Co., Ltd. (JP) 2010-07-14 — — EP disclosed
CN-101759628-A Ethynylindole compounds ONO PHARMACEUTICAL CO 2010-06-30 — — CN disclosed
US-20100160647-A1 ETHYNYLINDOLE COMPOUNDS ONO PHARMACEUTICAL CO., LTD. (JP) 2010-06-24 — — US disclosed
US-20100016306-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-21 — — US disclosed
CN-101479277-A Pyrimidine derivatives as PI3K inhibitors PIRAMED LTD (CH) 2009-07-08 — — CN disclosed
US-20080004290-A1 Anti-Cancer Agents THE UNIVERSITY OF QUEENSLAND (AU) 2008-01-03 — — US disclosed
US-20080004290-A1 Anti-Cancer Agents THE UNIVERSITY OF QUEENSLAND (AU) 2008-01-03 — — US disclosed
EP-0715627-B1 INDOLE DERIVATIVES AS THROMBOXANE A2 ANTAGONISTS PFIZER LTD (GB) 1998-09-09 — — EP disclosed
US-5744488-A 1-CARBOXYALKYL-3-ALKYL OR PHENYL-5-ORGANOSULFONAMIDE OR -AMIDE INDOLES; ATHERSCLEROSIS; ANGINA; PREVENTING ANGIOPLASTY OCCULSION; THROMBOXANE SYNTHETASE INHIBITORS PFIZER INC. (US) 1998-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178063-A1 BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES PIK3CA, PIK3CD, PI4KA GAA 635/4885CYP1A2 1867/4885RXFP1 4443/4885
US-20240067667-A1 ORGANIC COMPOUND, MIXTURE, COMPOSITION, AND ORGANIC ELECTRONIC DEVICE ORC3, OR10J3, ESR1 GAA 2071/4885CYP1A2 143/4885RXFP1 4661/4885
US-20100160647-A1 ETHYNYLINDOLE COMPOUNDS CYSLTR2, CYSLTR1, LTB4R2 GAA 4840/4885CYP1A2 435/4885RXFP1 269/4885
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 GAA 4885/4885CYP1A2 104/4885RXFP1 57/4885
US-20240374588-A1 IRAK4 PROTACS IRAK4, IRAK2, IRAK3 GAA 3289/4885CYP1A2 4419/4885RXFP1 3133/4885
US-20100016306-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB GAA 2467/4885CYP1A2 1541/4885RXFP1 4496/4885
US-20080004290-A1 Anti-Cancer Agents TP53, TOP2A, MCL1 GAA 662/4885CYP1A2 2080/4885RXFP1 4470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.